The Genea078 human embryonic stem cell line was derived from a donated, fully commercially consented ART blastocyst, carrying compound heterozygous mutations in the NEB gene, exon 55 deletion & c.15110dupA, indicative of Nemaline Myopathy Type 2 (NEM2). Following ICM outgrowth on inactivated human feeders, karyotype was confirmed as 46, XX and STR analysis demonstrated a female Allele pattern. The hESC line had pluripotent cell morphology, 76% of cells expressed Nanog, 93% Oct4, 67% Tra1-60 and 97% SSEA4 and gave a Pluritest Pluripotency score of 42.18, Novelty of 1.37. The cell line was negative for Mycoplasma and visible contamination.
Institution
Genea 
Materials and methods

Cell line derivation
The human embryo was thawed and plated whole onto mitomycin C inactivated human feeders (Detroit 551 HFF -90,000/well in 4-well) in 20% Knock out serum in standard hESC culture medium (Amit et al., 2000) with 20 ng/mL Fgf2. CGH karyotyping and STR profiling were performed at the first cryobanking step from ICM outgrowths maintained on feeders. Cells were then enzymatically passaged as single cells in M2 pluripotent cell maintenance medium (Genea Biocells) and CGH/ karyotyping repeated, immunofluorescent pluripotent marker staining, pluritest and sterility testing performed.
Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal analysis: Passage 12 (10 on feeders, 2 enzymatic); CGH was used to screen targeted regions of the genome for gains and losses associated with chromosomal imbalances such as aneuploidy, deletions and duplications. CGH was performed using SurePrint G3 microarrays (8 × 60 K format) which were scanned with the Agilent Scanner C 2. Pluritest: Passage 12 (10 on feeders, 2 enzymatic); RNA was collected and subjected to a Pluritest, a bioinformatic assay of pluripotency in human cells based on gene expression profiles (Müller et al., 2012) .
Sterility testing
1. Mycoplasma: Passage 12 (10 on feeders, 2 enzymatic); testing was performed as per manufacturer's instructions using the MycoAlert Mycoplasma Detection Kit from LONZA.
2. Microbial contamination: testing was performed in conjunction with our QC measures. Cells were thawed and cultured in 7 mL antibiotic free medium (Genea Biocells M2 medium) for 2-3 days at 37°C. A clear solution at~48-72 h indicated lack of bacterial, fungal or yeast contamination. Clarity of the solution was assessed by Cell Production Team.
Verification and authentication
Ethics/consents Ethics approval for the project ('Derivation of human embryonic stem cells from embryos identified through pre-implantation genetic diagnosis to be affected by known genetic conditions') was obtained from the Genea Ethics Committee on 13 September 2005. Excess ART embryos were fully consented for stem cell derivation by all responsible people through an informed consent process (signed de-identified consent form can be provided upon request). Donors have received no payment or financial benefits for their donation. Genea078 has been derived from a donated, fully commercially consented embryo, originally created by assisted reproduction technology (ART) for the purpose of procreation. The embryo was identified through pre-implantation genetic diagnosis to be affected by a genetic mutation and was declared excess to reproductive needs. Derivation was performed under Australian National Health and Medical Research Council (NHMRC) licence 309710. This licence was issued to GENEA on 7 May 2007. More information about the licence can be obtained from the NHMRC webpage at http://www.nhmrc.gov.au/health-ethics/humanembryos-and-cloning/database-licences-authorising-use-excess-artembryos.
PGD analysis conclusion
Mutation; Compound heterozygous exon 55 deletion & c.15110dupA in NEB gene. Family tree; both parents are carriers. Nemaline Myopathy 2 (NEM2) affected.
Morphology
The derived stem cell line, Genea078, morphologically displays adherent monolayer of compact cells in well-defined colonies with high nuclear to cytoplasmic ratio and prominent nucleoli.
Genetic analysis
The cell line has been karyotype tested by CGH ( Table 1 , Supplementary Fig. 1 ), which demonstrated 46, XX karyotype, consistent with original derivation and pre-implantation genetic diagnosis (PGD). Analysis of STR markers showed Allele pattern consistent with female genotype ( Table 2 , Supplementary Fig. 2 ).
Pluripotency
GENEA078 is pluripotent by;
